ANANDA Posts Update On Its Clinical Trial Of CBD Drug For The Treatment Of Opioid Use Disorder

ANANDA Scientific Inc., a research focused bio-pharmaceutical company revealed the first patient enrolled in the clinical trial evaluating Nantheia ATL5, an investigational drug using CBD in ANANDA's proprietary delivery technology as an adjunctive treatment for opioid use disorder.

This trial is being led by principal investigators Edythe London, Ph.D., distinguished professor of psychiatry and biobehavioral sciences as well as molecular and medicinal pharmacology at the Semel Institute, Geffen School of Medicine UCLA, and Richard De La Garza II, Ph.D., professor of psychiatry and biobehavioral sciences at the Semel Institute, Geffen School of Medicine UCLA. Funding for this trial is from the National Institute on Drug Abuse.

"We are delighted to have the first patient enrolled in this important trial of our investigational drug Nantheia ATL5. This clinical study is an important component of our clinical development efforts focused on opioid addiction, where a non-addictive therapy is a significant unmet need," stated Sohail R. Zaidi, ANANDA's CEO. "We are impressed by the clinical competence and operational diligence of the clinical trial team at UCLA which makes them our partner of choice for future trials as we develop the clinical program"

This will be a randomized, double-blind, placebo controlled, sequential, dose-ranging study of CBD (600, 1200 mg/day) as an adjunctive therapy to buprenorphine and naloxone in patients who have opioid use disorder and are receiving residential behavioral therapy, including cognitive behavioral therapy. The primary endpoint will be safety and tolerability of CBD in these patients, Secondary measures will include cue-induced craving, reductions in spontaneous craving, opioid withdrawal, negative affective states, and relapse, as well as retention in treatment with buprenorphine and naloxone.

Photo by Diyahna Lewis on Unsplash

Related News

University Of Nebraska Medical Center And ANANDA Scientific Get FDA Approval For Clinical Trial Of CBD-Based Drug For PTSD